Schroder Investment Management Group Has $6.80 Million Holdings in Scholar Rock Holding Corporation $SRRK

Schroder Investment Management Group grew its holdings in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 217.1% in the 2nd quarter, Holdings Channel reports. The fund owned 191,998 shares of the company’s stock after buying an additional 131,458 shares during the period. Schroder Investment Management Group’s holdings in Scholar Rock were worth $6,801,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Scholar Rock by 12.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,557 shares of the company’s stock valued at $597,000 after purchasing an additional 2,051 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Scholar Rock in the first quarter valued at approximately $71,000. XTX Topco Ltd bought a new stake in shares of Scholar Rock during the first quarter worth $422,000. Vanguard Group Inc. increased its holdings in shares of Scholar Rock by 2.1% during the first quarter. Vanguard Group Inc. now owns 4,845,205 shares of the company’s stock worth $155,773,000 after buying an additional 101,723 shares in the last quarter. Finally, Swiss National Bank lifted its stake in shares of Scholar Rock by 10.1% in the 1st quarter. Swiss National Bank now owns 127,000 shares of the company’s stock valued at $4,083,000 after acquiring an additional 11,600 shares during the last quarter. Institutional investors own 91.08% of the company’s stock.

Wall Street Analyst Weigh In

SRRK has been the topic of a number of recent research reports. Wolfe Research began coverage on Scholar Rock in a research note on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target on the stock. HC Wainwright dropped their price objective on shares of Scholar Rock from $50.00 to $44.00 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Wednesday, October 8th. Leerink Partners started coverage on shares of Scholar Rock in a research report on Monday, September 15th. They issued an “outperform” rating and a $51.00 price target for the company. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a report on Friday, November 14th. Four investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $48.33.

Scholar Rock Stock Performance

Shares of Scholar Rock stock opened at $45.20 on Friday. The business has a 50-day moving average price of $34.97 and a two-hundred day moving average price of $34.36. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $46.98. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The company has a market cap of $4.61 billion, a P/E ratio of -14.35 and a beta of 0.61.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the prior year, the company posted ($0.66) earnings per share. As a group, analysts anticipate that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Insiders Place Their Bets

In related news, Director Katie Peng sold 1,006 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $32.53, for a total transaction of $32,725.18. Following the transaction, the director directly owned 33,914 shares of the company’s stock, valued at $1,103,222.42. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Srinivas Akkaraju purchased 387,414 shares of Scholar Rock stock in a transaction on Friday, October 3rd. The stock was bought at an average price of $37.27 per share, with a total value of $14,438,919.78. Following the completion of the acquisition, the director directly owned 387,414 shares of the company’s stock, valued at approximately $14,438,919.78. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have sold 7,537 shares of company stock worth $242,088. Corporate insiders own 13.30% of the company’s stock.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.